Disease Progress Models

Principles of Clinical Pharmacology

Volumn , Issue , 2007, Pages 313-321

  Holford, Nicholas H G ^a   Mould, Diane R ^b   Peck, Carl C ^c,d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Projections Research Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UC Davis Washington Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877055606     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369417-1/50060-2     Document Type: Chapter

References (17)

1. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981, 6:429-453.
2. Sheiner LB. Clinical pharmacology and the choice between theory and empiricism. Clin Pharmacol Ther 1989, 46:303-309.
3. Sheiner LB. Learning versus confirming in clini-cal drug development. Clin Pharmacol Ther 1997, 61:187-195.
4. Holford NHG, Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther 1982, 16:681-684.
5. Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. Prednisone in Duchenne Dystrophy: A randomized controlled trial defining the time course and dose response. Arch Neurol 1991, 48:273-322.
6. Sale M, Sheiner LB, Volberding P, Blaschke TF. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther 1993, 54:107-112.
7. Holford NHG Population models for Alzheimer's and Parkinson's disease. The population approach: Measuring and managing variability in response, concentration and dose 1997, 387-393. COST B1 European Commission, Brussels. A. L, B. LP (Eds.).
8. Holford NHG, Peace KE. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 1992, 89:727-732.
9. Holford NHG Physiological alternatives to the effect compartment model. Advanced methods of pharmacokinetic and pharma-codynamic systems analysis 1991, iv-vii. Plenum Press, New York. D. DZ (Ed.).
10. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993, 21:35-41.
11. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density serum cholesterol concentra-tions and uterine endometrium in postmenopausal women. N Engl J Med 1997, 337:173-201.
12. Holford NHG, Chan PL, Nutt JG, Kieburtz K, Shoulson I Disease progression and pharmacody-namics in Parkinson disease - evidence for func-tional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn. 2006, 33(3):42-57. Jun.
13. Jusko W. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci 1971, 60:423-447.
14. Zhi J, Nightingale C, Quintiliani R. A pharma-codynamic model for the activity of antibiotics against microorganisms under non saturable condi-tions. J Pharm Sci 1986, 25:1095-1101.
15. Jusko W. A pharmacodynamic model for cell cycle-specific chemotherapeutic agents. J Pharmacokinet Biopharm 1973, 1:555-567.
16. Prior JC, Vigna YM, Schulzer M, Hall JE, Bonen A. Determination of luteal phase length by quantitative basal temperature methods: Validation against the midcycle LH peak. Clin Invest Med 1990, 13:472-478.
17. Yano Y, Oguma T, Nagata H, Sasaki S. Applica-tion of a logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 1998, 87.